R
Roivant Sciences Ltd. (ROIV)
NMS – Real vaqt narxi. Valyuta: USD
29.39
+0.43 (1.48%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NMS – Real vaqt narxi. Valyuta: USD
29.39
+0.43 (1.48%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Roivant Sciences Ltd. klinik bosqichdagi biofarmatsevtika kompaniyasi bo'lib, dori vositalari va texnologiyalarni kashf qilish, ishlab chiqish va tijoratlashtirishga qaratilgan. Uning klinik mahsulot nomzodlari orasida IMVT-1402, grevs kasalligi, davolash qiyin bo'lgan revmatoid artrit, sjögren kasalligi, miyasteniya gravis, surunkali yallig'lanishli demiyelinatsiyalovchi polinevropatiya va teri qizil yugirigi ko'rsatkichlarini davolash uchun neonatali fragment kristall reseptorini maqsad qilgan to'liq inson monoklonal antikori; ko'zning tiroid kasalligini davolash uchun to'liq inson monoklonal antikori bo'lgan batoklimab; va dermatomiyozit, yuqumli bo'lmagan uveit, teri sarkoidozi va boshqa immunitet vositachiligidagi kasalliklarni davolash uchun ishlab chiqilayotgan TYK2 va JAK1 ning kuchli kichik molekulali inhibitori bo'lgan brepocitinib mavjud. Kompaniyaning asosiy dasturi interstitsial o'pka kasalligi bilan bog'liq o'pka gipertenziyasi va boshqa kardiopulmoner kasalliklarni davolash uchun inhalatsiya qilinadigan sGC aktivatori bo'lgan mosliciguatni o'z ichiga oladi. Mening kompaniya lipidli nanozarralar (LNP) platformasi va ligand kon'yugat platformasini o'z ichiga olgan yetkazib berish platformalarini taklif etadi. Roivant Sciences Ltd. 2014 yilda tashkil etilgan va London, Buyuk Britaniyada joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Eric Venker M.D., Pharm.D. | President & CEO of Immunovant |
| Dr. Frank M. Torti M.B.A., M.D. | President & Vant Chair |
| Dr. Huafeng Xu Ph.D. | Chief Technology Officer |
| Dr. Mayukh Sukhatme M.D. | President, Chief Investment Officer & Director |
| Mr. Ian Rosenblum | Chief Information Officer |
| Mr. Josh Chen J.D. | General Counsel |
| Mr. Matthew Gline | CEO & Director |
| Mr. Richard Pulik | Chief Financial Officer |
| Ms. Jennifer Humes | Chief Accounting Officer |
| Ms. Kelly Graff | Head of People |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-04-02 | 8-K | ef20069685_8k.htm |
| 2026-03-23 | 8-K/A | ef20068452_8ka.htm |
| 2026-03-03 | 8-K | ef20067067_8k.htm |
| 2026-02-06 | 8-K | roiv-20260206.htm |
| 2026-02-06 | 10-Q | roiv-20251231.htm |
| 2025-12-11 | 8-K | ef20061071_8k.htm |
| 2025-11-10 | 8-K | ef20058314_8k.htm |
| 2025-10-03 | S-3ASR | ny20056482x1_s3asr.htm |
| 2025-09-17 | 8-K | ef20055655_8k.htm |
| 2025-09-11 | 8-K | ef20055421_8k.htm |